Genetic susceptibility to disease (Z15) ICD-10-CM
The Z15 code range covers genetic susceptibility to disease with 18 ICD-10-CM diagnosis codes. 14 of them are billable and valid for claim submission in fiscal year 2026, and the category headers group them but cannot themselves be billed.
Includes
This note appears immediately under a three character code title to further define, or give examples of, the content of the category.
- confirmed abnormal gene
Use Additional Code
The “use additional code” indicates that a secondary code could be used to further specify the patient’s condition. This note is not mandatory and is only used if enough information is available to assign an additional code.
Type 1 Excludes
A type 1 excludes note is a pure excludes note. It means "NOT CODED HERE!" An Excludes1 note indicates that the code excluded should never be used at the same time as the code above the Excludes1 note. An Excludes1 is used when two conditions cannot occur together, such as a congenital form versus an acquired form of the same condition.
Codes in the Z15 Range 18 codes · 14 billable
- Z15 Genetic susceptibility to diseaseNon-billable
- Z15.0 Genetic susceptibility to malignant neoplasmNon-billable
- Z15.01 Genetic susceptibility to malignant neoplasm of breast
- Z15.02 Genetic susceptibility to malignant neoplasm of ovary
- Z15.03 Genetic susceptibility to malignant neoplasm of prostate
- Z15.04 Genetic susceptibility to malignant neoplasm of endometrium
- Z15.05 Genetic susceptibility to malignant neoplasm of fallopian tube(s) New
- Z15.06 Genetic susceptibility to malignant neoplasm of digestive systemNon-billable
- Z15.060 Genetic susceptibility to colorectal cancer New
- Z15.068 Genetic susceptibility to other malignant neoplasm of digestive system New
- Z15.07 Genetic susceptibility to malignant neoplasm of urinary tract New
- Z15.09 Genetic susceptibility to other malignant neoplasm
- Z15.1 Genetic susceptibility to epilepsy and neurodevelopmental disorders
- Z15.2 Genetic susceptibility to obesity
- Z15.3 Genetic susceptibility to kidney disease New
- Z15.8 Genetic susceptibility to other diseaseNon-billable
- Z15.81 Genetic susceptibility to multiple endocrine neoplasia [MEN]
- Z15.89 Genetic susceptibility to other disease
About the Z15 Code Range
The ICD-10 code Z15 series identifies patients with genetic susceptibility to various diseases, focusing primarily on inherited risks for types of cancer and other conditions. These codes are used to document and track individuals who carry genetic markers indicating a higher likelihood of developing specific diseases.
The section includes codes such as Z15.01 for genetic susceptibility to breast cancer, encompassing well-known markers like BRCA1 and BRCA2 gene mutations and Li-Fraumeni syndrome, helping clarify terms like "Breast cancer genetic marker of susceptibility detected." Other specific codes cover susceptibility to ovarian (Z15.02), prostate (Z15.03), and endometrial cancers (Z15.04), as well as a broader Z15.09 for other hereditary cancers, including Lynch syndrome and hereditary colorectal cancer mutations. Additionally, these codes address genetic susceptibility to non-cancer diseases, such as epilepsy (Z15.1), obesity (Z15.2), and multiple endocrine neoplasia (Z15.81). The naming of various syndromes and gene mutations under these codes guides medical coders in accurately capturing genetic risk factors, facilitating personalized patient care and preventative strategies.
Questions About This Page
How many billable codes are in the Z15 range?
Of the 18 codes in this range, 14 are billable and valid for claim submission from October 1, 2025 through September 30, 2026. Category header codes group them but cannot be reported on claims.
What does the Z15 range classify?
The range classifies genetic susceptibility to disease. Each code links to its own reference page with billing status, MS-DRG grouping, coding notes, and clinical information.
Related References
Source: CMS FY 2026 ICD-10-CM Tabular List and order file, effective October 1, 2025 through September 30, 2026.
